Major Depressive Disorder (DSM-IV) – Epidemiology – Mature Markets

DRG Epidemiology’s coverage of major depressive disorder (MDD) (DSM-IV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of MDD (DSM-IV) for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy for the major mature pharmaceutical markets.

DRG Epidemiology’s MDD (DSM-IV) forecast will answer the following questions:

• Of all people with MDD (DSM-IV), how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• Of all people diagnosed with MDD (DSM-IV), how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MDD (DSM-IV) over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, DRG Epidemiology forecasts four key MDD (DSM-IV) patient populations, as follows:

• Total prevalent cases.
• Diagnosed prevalent cases.
• Drug-treated prevalent cases.
• Treatment-resistant drug-treated prevalent cases.

Note: Coverage may vary by country.